Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
Psilocybin isn’t the only psychedelic that’s being studied for addiction treatment!
Awakn Life Sciences (AWKN) has received approval for the first-ever study on ketamine in gambling addiction – a disorder that affects 10 million people in the US alone, yet has no licensed pharmacological treatment.
The company will use ketamine-assisted psychotherapy to tackle the urge to gamble as well as superstitious thinking that’s at the root of the addition.
Awakn is also investigating the effects of ketamine and MDMA in treating alcohol use disorder (AUD).